Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Zallio F, et al. Among authors: mannina d. Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13. Br J Haematol. 2016. PMID: 26763986 Free article. Clinical Trial.
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M. Mannina D, et al. Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352. Leuk Lymphoma. 2010. PMID: 20038237
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M. Di Renzo N, et al. Among authors: mannina d. Support Care Cancer. 2011 Oct;19(10):1505-10. doi: 10.1007/s00520-010-0974-y. Epub 2010 Aug 8. Support Care Cancer. 2011. PMID: 20694798 Free PMC article. Clinical Trial.
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi. Ferrario A, et al. Among authors: mannina d. Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17. Ann Hematol. 2011. PMID: 20848104 Clinical Trial.
Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.
Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C, Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L. Ferrario A, et al. Among authors: mannina d. Cancer. 2012 Aug 15;118(16):3954-61. doi: 10.1002/cncr.26708. Epub 2011 Dec 16. Cancer. 2012. PMID: 22179904 Free article. Clinical Trial.
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions.
Falorio S, Biasoli I, Luminari S, Quintana G, Musso M, Dell'olio M, Specchia MR, di Renzo N, Cesaretti M, Buda G, Vallisa D, Mannina D, Andriani A, Chiattone CS, Delamain MT, de Souza CA, Spector N, Angrilli F, Federico M. Falorio S, et al. Among authors: mannina d. Hematol Oncol. 2013 Jun;31(2):72-8. doi: 10.1002/hon.2029. Epub 2012 Oct 2. Hematol Oncol. 2013. PMID: 23027689
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.
Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E. Ceriani L, et al. Among authors: mannina d. Blood. 2015 Aug 20;126(8):950-6. doi: 10.1182/blood-2014-12-616474. Epub 2015 Jun 18. Blood. 2015. PMID: 26089397 Free article. Clinical Trial.
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
Gentile M, Zirlik K, Ciolli S, Mauro FR, Di Renzo N, Mastrullo L, Angrilli F, Molica S, Tripepi G, Giordano A, Di Raimondo F, Selleri C, Coscia M, Musso M, Orsucci L, Mannina D, Rago A, Giannotta A, Ferrara F, Herishanu Y, Shvidel L, Tadmor T, Scortechini I, Ilariucci F, Murru R, Guarini A, Musuraca G, Mineo G, Vincelli I, Arcari A, Tarantini G, Caparrotti G, Chiarenza A, Levato L, Villa MR, De Paolis MR, Zinzani PL, Polliack A, Morabito F. Gentile M, et al. Among authors: mannina d. Eur J Cancer. 2016 Jun;60:154-65. doi: 10.1016/j.ejca.2016.03.069. Epub 2016 Apr 27. Eur J Cancer. 2016. PMID: 27127905
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.
Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R. Laurenti L, et al. Among authors: d arena g, mannina d. Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. Haematologica. 2017. PMID: 28596282 Free PMC article. No abstract available.
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL. Broccoli A, et al. Among authors: mannina d. Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3. Haematologica. 2017. PMID: 28775121 Free PMC article.
87 results